iX Biopharma Ltd. (SGX: 42C)
Singapore
· Delayed Price · Currency is SGD 0.0250
0.00 (0.00%)
At close: Oct 11, 2024
iX Biopharma Ratios and Metrics
Market cap in millions SGD. Fiscal year is July - June.
Millions SGD. Fiscal year is Jul - Jun.
Fiscal Year | Current | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Oct '24 Oct 10, 2024 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | 2019 - 2015 |
| Market Capitalization | 22 | 22 | 70 | 122 | 167 | 162 | Upgrade
|
| Market Cap Growth | -68.05% | -68.05% | -43.05% | -26.84% | 3.17% | -1.31% | Upgrade
|
| Enterprise Value | 25 | 22 | 62 | 111 | 162 | 156 | Upgrade
|
| Last Close Price | 0.03 | 0.03 | 0.09 | 0.16 | 0.24 | 0.24 | Upgrade
|
| PE Ratio | - | -2.06 | -7.14 | -25.99 | -19.94 | -15.06 | Upgrade
|
| PS Ratio | 3.22 | 3.74 | 11.79 | 8.51 | 95.91 | 164.69 | Upgrade
|
| PB Ratio | 4.43 | 5.13 | 4.40 | 6.20 | 14.29 | 15.95 | Upgrade
|
| P/FCF Ratio | -3.26 | -3.26 | -8.35 | 41.89 | -18.79 | -17.44 | Upgrade
|
| P/OCF Ratio | -3.40 | -3.40 | -9.10 | 39.21 | -20.04 | -19.50 | Upgrade
|
| EV/Sales Ratio | 4.27 | 3.73 | 10.51 | 7.70 | 92.74 | 157.93 | Upgrade
|
| EV/EBITDA Ratio | -3.13 | -3.13 | -6.87 | 96.40 | -15.00 | -14.79 | Upgrade
|
| EV/EBIT Ratio | -2.96 | -2.96 | -6.51 | 221.09 | -14.16 | -13.94 | Upgrade
|
| EV/FCF Ratio | -3.73 | -3.25 | -7.44 | 37.89 | -18.17 | -16.72 | Upgrade
|
| Debt / Equity Ratio | 1.20 | 1.20 | 0.27 | 0.22 | 0.36 | 0.39 | Upgrade
|
| Debt / EBITDA Ratio | - | - | - | 2.91 | - | - | Upgrade
|
| Debt / FCF Ratio | -0.76 | -0.76 | -0.52 | 1.51 | -0.48 | -0.42 | Upgrade
|
| Asset Turnover | 0.30 | 0.30 | 0.22 | 0.61 | 0.10 | 0.05 | Upgrade
|
| Inventory Turnover | 4.20 | 4.20 | 3.86 | 2.09 | 2.14 | 1.81 | Upgrade
|
| Quick Ratio | 0.65 | 0.65 | 1.34 | 1.98 | 2.19 | 2.14 | Upgrade
|
| Current Ratio | 0.89 | 0.89 | 1.53 | 2.14 | 2.55 | 2.47 | Upgrade
|
| Return on Equity (ROE) | -106.91% | -106.91% | -54.02% | -29.24% | -75.27% | -68.47% | Upgrade
|
| Return on Assets (ROA) | -23.69% | -23.69% | -22.32% | 1.32% | -39.86% | -31.95% | Upgrade
|
| Return on Capital (ROIC) | -31.51% | -31.51% | -26.91% | 1.56% | -47.57% | -36.32% | Upgrade
|
| Earnings Yield | -56.40% | -48.44% | -13.79% | -3.76% | -4.92% | -6.47% | Upgrade
|
| FCF Yield | -30.91% | -30.64% | -11.98% | 2.39% | -5.32% | -5.74% | Upgrade
|
| Buyback Yield / Dilution | -0.33% | -0.33% | -2.51% | -7.60% | -7.13% | -0.54% | Upgrade
|
| Total Shareholder Return | -0.33% | -0.33% | -2.51% | -7.60% | -7.13% | -0.54% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.